Percutaneous microwave ablation of bone tumors: a systematic review
- 6 November 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in European Radiology
- Vol. 31 (5), 3530-3541
- https://doi.org/10.1007/s00330-020-07382-8
Abstract
Aim To systematically review microwave ablation (MWA) protocols, safety, and clinical efficacy for treating bone tumors. Materials and methods A systematic literature search was conducted using PubMed, the Cochrane Library, EMBASE, and Web of Science database. Data concerning patient demographics, tumor characteristics, procedure, complications, and clinical outcomes were extracted and analyzed. Results Seven non-comparative studies (6 retrospective, 1 prospective) were included accounting for 249 patients and 306 tumors (244/306 [79.7%] metastases; 25/306 [8.2%] myelomas, and 37/306 [12.1%] osteoid osteomas [OO]). In malignant tumors, MWA power was 30–70 W (except in one spinal tumors series where a mean power of 13.3 W was used) with pooled mean ablation time of 308.3 s. With OO, MWA power was 30–60 W with mean ablation time of 90–102 s. Protective measures were very sporadically used in 5 studies. Additional osteoplasty was performed in 199/269 (74.0%) malignant tumors. Clinically significant complications were noted in 10/249 (4.0%) patients. For malignant tumors, estimated pain reduction on the numerical rating scale was 5.3/10 (95% confidence intervals [95%CI] 4.6–6.1) at 1 month; and 5.3/10 (95% CI 4.3–6.3) at the last recorded follow-up (range 20–24 weeks in 4/5 studies). For OO, at 1-month follow-up, effective pain relief was noted in 92.3–100% of patients. Conclusion MWA is effective in achieving pain relief at short- (1 month) and mid-term (4–6 months) for painful OO and malignant bone tumors, respectively. Although MWA seems safe, further prospective studies are warranted to further assess this aspect, and to standardize MWA protocols. Key Points • Large heterogeneity exists across literature about ablation protocols used with microwave ablation applied for the treatment of benign and malignant bone tumors. • Although microwave ablation of bone tumors appears safe, further studies are needed to assess this aspect, as current literature does not allow definitive conclusions. • Nevertheless, microwave ablation is effective in achieving pain relief at short- (1 month) and mid-term (4–6 months) for painful osteoid osteomas and malignant bone tumors, respectively.Keywords
This publication has 32 references indexed in Scilit:
- Combined Microwave Ablation and Cementoplasty in Patients with Painful Bone Metastases at High Risk of FractureCardioVascular and Interventional Radiology, 2015
- Microwave ablation of focal hepatic malignancies regardless of size: A 9-year retrospective study of 64 patientsEuropean Journal of Radiology, 2015
- Microwave Thermal Ablation of Spinal Metastatic Bone TumorsJournal of Vascular and Interventional Radiology, 2014
- Percutaneous image‐guided cryoablation of painful metastases involving boneCancer, 2012
- Palliation of Painful Metastatic Disease Involving Bone With Imaging-Guided Treatment: Comparison of Patients' Immediate Response to Radiofrequency Ablation and CryoablationAmerican Journal of Roentgenology, 2011
- Quality Improvement Guidelines for Bone Tumour ManagementCardioVascular and Interventional Radiology, 2010
- Microwave Ablation Technology: What Every User Should KnowCurrent Problems in Diagnostic Radiology, 2009
- Percutaneous Image-Guided Radiofrequency Ablation of Painful Metastases Involving Bone: A Multicenter StudyJournal of Clinical Oncology, 2004
- Osteoid Osteoma: Percutaneous Treatment with Radiofrequency EnergyRadiology, 2003
- Metastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treatment Reviews, 2001